聚ADP核糖聚合酶-1与原发性肝癌的研究进展  

Research Progress of PARP1 in Hepatocellular Carcinoma

作　　者：阙克婷 刘作金[1] 李钺[1] 

机构地区：[1]重庆医科大学附属第二医院肝胆外科,重庆

出　　处：《临床医学进展》2022年第7期6893-6899,共7页Advances in Clinical Medicine

摘　　要：最新统计数据表明,原发性肝癌(hepatocellular carcinoma, HCC)是世界上第二大致病率肿瘤,它有很高的复发率及很低的5年生存率,且它的治疗选择有限。然而每年的新发例数却在逐年增加。找到原发性肝癌复发、转移及耐药的机制是我们亟待解决的问题。聚ADP核糖聚合酶-1 (poly(ADP)-ribose polymerase, PARP1)是一个分子量为116 kDa的细胞核蛋白,它在多种肿瘤当中异常表达,包括卵巢癌、乳腺癌、前列腺癌、胰腺以及原发性肝癌。近年来目前上市的PARP抑制剂(PARP inhibitor, PARPi)药物,在乳腺及卵巢癌中应用广泛,但在原发性肝癌中不尽如意。原发性肝癌具有异质性,其发生与发展是一个多途径、多基因参与及多步骤的过程,其发病率与病死率在中国逐年上升。研究发现,PARP1与HCC的发生、发展及治疗密切相关,本文从PARP1的分子结构及生物学功能、PARPi的作用机制、PARP1在HCC组织中的表达情况、PARPi与HCC治疗的关系等4个方面对PARPi在HCC中作用的研究进展作一系统综述,为临床治疗HCC寻找新的治疗策略。The latest statistics show that hepatocellular carcinoma (HCC) is the second most morbid tumor in the world, which has a high recurrence rate, a low 5-year survival rate, and its treatment options are limited. However, the number of new cases is increasing year by year. It is urgent to find out the mechanism of recurrence, metastasis and drug resistance of HCC. Poly ADP-ribose polymerase-1 (poly(ADP)-ribose polymerase, PARP1) is a nuclear protein with a molecular weight of 116 kDa which is abnormally expressed in a variety of tumors, including ovarian cancer, breast cancer, prostate cancer, Pancreatic cancer and HCC. In recent years, the PARP inhibitor (PARPi) drugs cur-rently are widely used in breast and ovarian cancer. However, they are not satisfactory in HCC. HCC is a multi-path, multi-gene and multi-step process for its occurrence and development. Studies have found that PARP1 is closely related to the occurrence, development and treatment of HCC. This study focuses on the molecular structure and biological function of PARP1, the mechanism of action of PARPi, the expression of PARP1 in HCC tissue, and the relationship between PARPi and HCC treatment. A systematic review of the research progress of the role of PARPi in HCC was made to find new therapeutic strategies for clinical treatment of HCC.

关 键 词：聚ADP核糖聚合酶-1 (Poly(ADP)-Ribose Polymerase PARP1) 原发性肝癌(HCC) PARP抑制剂(PARPi) 

分 类 号：R735.7[医药卫生—肿瘤]